Highlights
- Imugene has appointed Dr Paul Woodard as chief medical officer.
- Dr Woodard carries extensive haematology and oncology experience gained from academia and industry.
- He has worked on number of drug development projects, focused on non-malignant haematologic disorders, haematologic malignancies, and solid tumours.
Imugene Limited (ASX: IMU) has updated on the appointment of Dr Paul Woodard as chief medical officer.
Dr Woodard has extensive clinical development experience and haematology and oncology background gained in industry and academia. He has worked on drug development projects in non-malignant haematologic disorders, haematologic malignancies and solid tumours.
Data Source: Company update
Rich experience of Dr Woodard
Dr Woodard worked in the following organisations –
Data source: company update
His academic experience centred on paediatric haematopoietic stem cell transplantation and haematologic disorders.
Educational background
Dr Woodard completed his B.A. in Chemistry and M.D. from the University of North Carolina. As part of the post-graduation journey, he completed fellowships at the University of North Carolina and the University of Minnesota. The post-grad journey also included a Residency at the University of Virginia.
IMU shares traded at AU$0.065 apiece at the time of writing on 4 September 2023.